The Pharma Data

JANUARY 27, 2021

MultiStem ® cell therapy is a patented regenerative medicine product candidate in clinical development that has shown the ability to promote tissue repair and healing in a variety of ways, such as through the production of therapeutic factors in response to signals of inflammation and tissue damage. 28, 2021 11:00 UTC.

Clinical Trials 52

Clinical Trials Clinical Trials Production Trials 52

The Pharma Data

NOVEMBER 15, 2020

NASDAQ: ATHX), a clinical-stage regenerative medicine company, is pleased to announce that it has appointed Ms. 16, 2020 11:00 UTC. CLEVELAND–( BUSINESS WIRE )– Athersys, Inc. Katherine Kalin, Ms. Jane Wasman and Mr. Baiju R. Shah to its board of directors. About MultiStem ®.

Clinical Trials 40

Clinical Trials Clinical Trials Production Trials 40

Drug Discovery World

FEBRUARY 2, 2023

A late-stage clinical trial in head and neck cancer for the treatment of severe oral blistering or oral mucositis caused by radiation therapy is planned.

Manufacturing 52

Manufacturing Clinical Trials Clinical Trials Drugs 52

The Pharma Data

MAY 4, 2021

Internal Medicine. billion, primarily driven by Pfizer CentreOne, Pfizer’s contract manufacturing operation, reflecting sales of legacy Upjohn products to Viatris (4) and remdesivir to Gilead Sciences Inc., Clinical and Research Developments. REVENUES. . . . . . ($ in millions). First-Quarter. . 1,611. . *. *.

Vaccination 40

Vaccination Vaccine Production Sales 40